Aclaris Therapeutics (ACRS) | Stock Overview & Key Data
Aclaris Therapeutics Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $33.88 on December 14, 2015
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Aclaris Therapeutics
ACRS
|
600.55M Small-cap | 1.79% | 15.45% | 33.65% | 28.22% | 97.22% | 193.88% | -57.73% | -76.38% | -77.18% | -65.44% | -65.44% |
|
Vertex
VRTX
|
109.45B Large-cap | 1.69% | 3.09% | -3.36% | -1.15% | -0.37% | -2.31% | 27.89% | 136.85% | 413.01% | 888.51% | 1,245.83% |
|
Regeneron
REGN
|
80.98B Large-cap | 0.60% | -11.93% | -18.75% | -18.29% | -20.78% | 15.66% | -21.83% | 13.80% | 72.82% | 1,033.17% | 4,804.97% |
|
Capricor
CAPR
|
2.04B Mid-cap | 2.14% | -7.19% | -12.57% | 0.64% | -5.62% | 119.02% | 445.45% | 385.88% | -42.15% | -92.18% | -98.04% |
|
Zymeworks
ZYME
|
1.96B Small-cap | -2.80% | -2.80% | -1.52% | -10.44% | -12.62% | 80.58% | 181.77% | -36.88% | 76.00% | 76.00% | 76.00% |
|
Amylyx
AMLX
|
1.91B Small-cap | 16.76% | 14.38% | 5.63% | 20.94% | 33.01% | 164.31% | -38.88% | -19.26% | -19.26% | -19.26% | -19.26% |
Ownership & Short Interest
Calculate Your Aclaris Therapeutics Investment Returns
Long-Term Investment Performance Analysis
Aclaris Therapeutics stock price in Jul 2016 was $20.91, A $1,000.00 lump sum investment in Aclaris Therapeutics made 10 years ago would be worth approximately $271.64 today, representing a negative return of -72.84%. This translates to an annualized return (CAGR) of -12.22%.
9 Years 11 Months Investment Scenario (Jul 2016 - Jul 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is ACRS's 52-week high and low?
- In the last 52 weeks, Aclaris Therapeutics reached a high of $5.85 (on July 9, 2026) and a low of $1.46 (on July 31, 2025).
- What is the market cap and P/E ratio for ACRS?
- Curious about Aclaris Therapeutics's size and valuation? Its market capitalization stands at 600.55M. When it comes to valuation, the P/E ratio (trailing twelve months) is N/A, and the forward P/E (looking ahead) is -5.76.
- Does ACRS pay dividends? If so, what's the yield?
- As for dividends, Aclaris Therapeutics isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Aclaris Therapeutics's main competitors or similar companies to consider before investing?
When looking at Aclaris Therapeutics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX109.45B Healthcare Biotechnology -2.31% 27.89% Regeneron
REGN80.98B Healthcare Biotechnology 15.66% -21.83% Capricor
CAPR2.04B Healthcare Biotechnology 119.02% 445.45% Zymeworks
ZYME1.96B Healthcare Biotechnology 80.58% 181.77% Amylyx
AMLX1.91B Healthcare Biotechnology 164.31% -38.88% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Aclaris Therapeutics Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Aclaris Therapeutics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -50.20%, the Debt to Equity ratio from the most recent quarter is 2.05, and its Gross Profit Margin stands at -13.44%.
- What is the recent revenue and earnings growth for ACRS?
- Looking at Aclaris Therapeutics's growth, its revenue over the trailing twelve months (TTM) was $8M. Compared to the same quarter last year (YoY), quarterly revenue grew by -85.90%, and quarterly earnings saw a YoY growth of -85.94%.
- How much of ACRS stock is held by insiders and institutions?
- Wondering who owns Aclaris Therapeutics stock? Company insiders (like executives and directors) hold about 2.57% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 84.06%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.